<DOC>
	<DOC>NCT01294423</DOC>
	<brief_summary>This is a 24-week randomised, multi-centre phase III study to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with Type 2 diabetes mellitus who have inadequate glycemic control with diet and exercise.</brief_summary>
	<brief_title>Evaluate Efficacy and Safety in Japanese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Men or women age ≥20 years old (Either gender needs to be 40% or higher of total number of treated subjects)diagnosed with type 2 DM ; ≥6.5% and ≤10% at 1 week before randomization Type 1 diabetes mellitus FPG &gt;240 mg/dL before randomization Subjects who have history of unstable or rapidly progressing renal disease Subjects who have severe hepatic insufficiency and/or significant abnormal liver function Significant cardiovascular history</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Phase3</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Type2 Diabetes Mellitus</keyword>
</DOC>